Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics Inc. (Nasdaq: BEAM) will have its CEO, John Evans, participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Oct. 5, 2021, at 8:00 a.m. ET. The event will be streamed live and accessible through the investor section of Beam's website, where it will remain archived for 60 days. Beam Therapeutics is focused on precision genetic medicines using innovative base editing technology, aimed at developing effective treatments while maintaining a commitment to cutting-edge science and patient care.
Beam Therapeutics (Nasdaq: BEAM) announced promising preclinical data at the 2021 International HBV Meeting regarding its cytosine base editors (CBEs) targeting hepatitis B virus (HBV). The study demonstrated significant reductions in viral markers, including HBsAg, utilizing multiplexing techniques. Results indicated a 30%-60% editing efficiency of cccDNA without reducing its levels, and a 20% enhanced efficacy when combined with standard antiviral treatment. Beam plans to advance its base editing approach to in vivo proof of concept models, highlighting its potential in treating chronic HBV infection.
Beam Therapeutics (Nasdaq: BEAM) announced new preclinical data on September 23, 2021, showcasing advancements in their lipid nanoparticle (LNP) formulations for in vivo liver editing. Key findings include up to 60% editing potency at 1.0 mg/kg in non-human primates (NHPs) and well-tolerated formulations at doses up to 1.5 mg/kg. The company also highlighted potential applications for delivering base editors beyond the liver to hematopoietic stem and progenitor cells (HSPCs). These developments may support future therapeutic applications for genetic diseases.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in the 2021 Wells Fargo Virtual Healthcare Conference, where CEO John Evans will engage in a fireside chat on Sept. 10, 2021, at 9:20 a.m. ET. The event will be accessible via a live webcast on the company's investor website, with an archive available for 60 days post-event. Beam Therapeutics focuses on precision genetic medicines through its innovative base editing technology, which allows for precise single base changes in DNA without double-stranded breaks, aiming to provide long-term cures for serious diseases.
Beam Therapeutics reported significant progress in its base editing programs, with plans to submit its first IND for BEAM-101 in H2 2021. The company initiated IND-enabling studies for BEAM-201 targeting T-cell acute lymphoblastic leukemia. Financially, Beam's Q2 2021 net loss was $76.3 million, or $1.23 per share, compared to $34.2 million, or $0.69 per share, in Q2 2020. With a cash position of $615.3 million, the company is well-equipped to advance its innovative pipeline, including partnerships to expand therapeutic applications. Upcoming presentations scheduled for August and September 2021 will further highlight their advancements.
Beam Therapeutics (Nasdaq: BEAM) announced that its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., will speak at the 2021 Wedbush PacGrow Healthcare Conference on Aug. 10, 2021, at 9:10 a.m. ET. The panel discussion, titled “So Let it Be (Re)Written - Updates in Gene Modulation,” will be available via a live webcast on the company's investor website and archived for 60 days. Beam Therapeutics specializes in precision genetic medicines through its proprietary base editing technology, allowing precise genomic alterations without DNA breaks.
Beam Therapeutics, a precision genetic medicine company (Nasdaq: BEAM), announced that CEO John Evans will speak at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 1:00 p.m. ET. The event will feature a live webcast accessible via the company's investor section on their website, with an archive available for 60 days post-event.
Beam specializes in base editing technology, enabling precise genetic alterations without DNA breaks, and is committed to developing lifelong cures for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) has announced that its CEO, John Evans, will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:30 a.m. ET. The live webcast will be accessible in the investor section of Beam's website and will be archived for 60 days post-event.
Beam specializes in precision genetic medicines through base editing, a technology allowing precise changes to DNA sequences without double-stranded breaks. The company is dedicated to advancing a diversified portfolio of gene editing programs aimed at treating serious diseases.
Beam Therapeutics, a biotechnology company, reported promising advances in its base editing platform and pipeline, with in vivo editing in liver cells of non-human primates reaching 52%. The company is on track to submit its first IND application for BEAM-101 in the second half of 2021. Cash reserves stood at $503.5 million, a significant increase from $253.4 million year-over-year. However, R&D expenses surged to $190.1 million, largely due to the acquisition of Guide Therapeutics, contributing to a net loss of $201.6 million.
Beam Therapeutics (Nasdaq: BEAM) announced the presentation of its base editing data at the upcoming ASGCT Annual Meeting, scheduled for May 11-14, 2021. During this event, Beam will demonstrate advancements in its base editing technology, aimed at treating serious genetic diseases. Key presentations include a workshop on gene editing and a poster session highlighting the use of lipid nanoparticles for delivery. The company is advancing towards filing an IND application for its lead program, BEAM-101, and is working on its first liver development candidate.